Mar. 16 at 10:50 AM
Canaccord just upgraded Seres Therapeutics with a
$22 price target.
With the stock currently at
$8.63, that’s a potential upside of roughly +155% (Ser 155 🙃)
But the upgrade isn’t the only thing catching attention. With Seres’ assets, its strategic positioning, and growing interest from larger players in the microbiome space, a buyout scenario is becoming increasingly realistic. The valuation gap is huge, and Seres could be a fast, strategic acquisition for any pharma looking to strengthen its pipeline.
This upgrade might be the first real signal.
$MCRB $MRK $NSRGY #Canaccord #BuyoutPotential